3Leclercq R, Courvalin P. Emerging problems with enterococcal infections[J]. Curr Opin Infect Dis, 1996, 9(1): 115-119
4Thal LA, Donabedian S, Robinso-Dun B, et al. Molecular analysis of glycopeptid e-resistant Enterococcus faecium isolates collected from Michigan hospitals ove r a 6-year period[J]. J Clin Microbiol, 1998, 36(11):3303-3308
5Jones RN, Marshall SA, Pfaller MA, et al. Nosocomial enterococcal blood stre am infections in the SCOPE Program: antimicrobial resistance, species occurrence , molecular testing results, and laboratory testing accuracy. SCOPE Hospital Stu dy Group[J]. Diagn Microbiol Infect Dis, 1997, 29(2): 95-102
6Perlada DE, Smulian AG, and Cushion MT. Molecular epidemiology and antibioti c susceptibility of enterococci in Cincinnati, Ohio:a prospective citywide surve y[J]. J Clin Microbiol, 1997,35(9):2342-2347
7Nelson RR, McGregor KF, Brown AR, et al. Isolation and characterization of glycopeptide-resistant enterococci from hospitalized patients over a 30-month period[J]. J Clin Microbiol, 2000, 38(6): 2112-2116
8Spencer RC, Bauernfeind A, Garcia-Rodriguez J, et al. Surveillance of the cu rrent resistance of nosocomial pathogens to antibacterials[J]. Clin Microbio l Infect, 1997, 3(Suppl 1):s21-35
